Ignite Creation Date:
2024-05-19 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06415227
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-16
First Post:
2024-04-25
Brief Title:
The Impact of Vericiguat on Microvascular Function in Patients With Documented Vasospastic Angina Pectoris
Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam AMC-UvA
Organization:
Academisch Medisch Centrum - Universiteit van Amsterdam AMC-UvA
Study Overview
Official Title:
Vericiguat in Vasospastic Angina
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ViVA
Brief Summary:
Vasospastic angina is increasingly recognized as an important contributor to anginal symptoms in patients with non-obstructive coronary artery disease ANOCA Endothelial dysfunction and smooth muscle cell dysfunction are considered elementary in the development of vasospastic angina As one of many functions the vascular endothelium regulates local vascular tone mainly through the vasodilatory effect of endothelium-derived nitric oxide NO Vericiguat is a soluble guanylate cyclase sGC stimulator and thereby acts directly on the NO signalling pathway from the endothelium towards the vascular smooth muscle cells As such Vericiguat potentially has an beneficial therapeutic effect in patients with vasospastic anginaThe VIVA study aims to demonstrate the effect of Vericiguat on endothelial function and microvascular vasodilator responses as well as its tolerability and safety in patients with vasospastic angina as the pathophysiological substrate of ANOCA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None